Product Description
Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis. RB-PDAT can be considered as an adjunct therapy for cases of severe, progressive infectious keratitis before performing a therapeutic keratoplasty. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31493402/)
Mechanisms of Action: CRAC Stimulant
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Ireland | New Zealand | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Provectus
Company Location: KNOXVILLE TN 37932
Company CEO: Bruce Horowitz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Keratitis|Acanthamoeba Keratitis|Stomatitis, Denture|Tobacco Use Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REAGIR II | P3 |
Recruiting |
Keratitis |
2025-07-01 |
|
| REAGIR | P3 |
Active, not recruiting |
Acanthamoeba Keratitis |
2025-01-31 |
|
| ChiCTR2200066207 | N/A |
Not yet recruiting |
Pterygium |
2024-12-31 |
|
| KingSaudUni | P3 |
Unknown status |
Tobacco Use Disorder|Stomatitis, Denture |
2020-12-12 |